Cornerstone BioPharma, Inc. Appoints Alastair McEwan as CFO

Released on = September 29, 2005, 6:28 am

Press Release Author = 919 Marketing

Industry = Human Resources

Press Release Summary = Cornerstone BioPharma, Inc., the Triangle-based specialty pharmaceutical company focused in the CNS (central nervous system), anti-infective, and respiratory markets, today announced Alastair McEwan has joined the company as Chief Financial Officer. McEwan will also be appointed to the company’s Board of
Directors.

Press Release Body = Cornerstone BioPharma, Inc., the Triangle-based specialty pharmaceutical company focused in the CNS (central nervous system), anti-infective, and respiratory markets, today announced Alastair McEwan has joined the company as Chief Financial Officer. McEwan will also be appointed to the company’s Board of
Directors.

McEwan has a successful track record of increasing the scale and profitability of businesses in a number of sectors, including biotechnology and pharmaceutical services. He has substantial experience in fund raising activities at all levels and has participated in two successful IPOs, most recently while at Inveresk Research
Group where he served as a member of the Group Executive Board as well as President of the Global Clinical division. Prior to Inveresk, McEwan was the Managing Director of CHC’s European healthcare IT activities from 1990 through 1994.

“Cornerstone is a company that has seen exceptional growth and accomplishment since its foundation. Its success is a testament to Craig Collard and his colleagues and I am very pleased to have the opportunity to work with them as the company progresses to the next stage of its development. I believe that we have outstanding
potential for accelerating its path of profitable growth,” commented McEwan.

McEwan will join Jim Baker, President and CEO of Atlantic Search Group Inc., Philip Pesin, founding partner of the California based law firm, Pesin & Blatz, and Cornerstone Founder and CEO, Craig Collard on the company’s Board of Directors.

“Alastair will no doubt be an invaluable member of the Cornerstone team. His 25 years of experience in all aspects of business, particularly finance, mergers and acquisitions, and strategic planning will provide Cornerstone with added expertise that will support our continued growth and expansion,” said Collard.

McEwan moved to the United States in 2001 following Inveresk’s acquisition of the ClinTrials Research Group. He holds a Bachelors of Commerce degree from the University of Edinburgh, and is a Chartered Accountant and a Member of the Institute of Directors

# # #

ABOUT CORNERSTONE BIOPHARMA, INC.
Cornerstone BioPharma, Inc., located next to North Carolina’s Research Triangle Park, is an emerging specialty pharmaceutical company that is currently focused on the development and commercialization of niche prescription medications in the CNS,
anti-infective, and respiratory markets. The privately held company owns the rights to a pain product line, three respiratory product lines, and co-promotes the Suprax® antibiotic. Cornerstone is actively engaged in the licensing of additional prescription products in niche markets through acquisitions and strategic partnerships.

Web Site = http://www.cornerstonebiopharma.com

Contact Details = Kim Knoblauch
919 Marketing
919.557.7890
kknoblauch@919marketing.com